Tumor immunoglobulin idiotype (None)

The **tumor immunoglobulin idiotype** refers to the unique variable region antigenic determinants (idiotopes) found on the surface immunoglobulin (antibody) molecules expressed by malignant B cells. Each B-cell lymphoma or myeloma clone expresses an immunoglobulin with a distinct idiotype, derived from the specific sequence of its variable region. This idiotype functions as a **tumor-specific antigen**, making it a target for immunotherapy approaches including monoclonal antibodies, customized protein or DNA vaccines, and antigen-loaded dendritic cell therapies. Although the concept has demonstrated proof-of-principle efficacy in academic studies—eliciting both antibody and T-cell responses—practical application faces significant hurdles due to the requirement for patient-specific customization, tumor immune escape via idiotype loss/mutation, and logistical limitations that have hindered widespread clinical adoption[1][2][3][4][5][6][7].

Other names

IdiotypeTumor-specific immunoglobulin idiotypeImmunoglobulin idiotype antigensIg idiotype (surface immunoglobulin idiotype)

Immune activation via induction of anti-idiotype antibody responses (passive immunotherapy); Active immunization (generation of T-cell and antibody responses specific for the tumor clone); Antigen presentation (dendritic cell vaccines presenting idiotype protein to T cells)